Flupirtine Determination in Human Blood Plasma by HPLC with Mass-Spectrometric Detection and its Application to Pharmacokinetic Studies


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A validated method for quantitative determination of flupirtine in human blood plasma using liquid chromatography combined with tandem mass spectrometry (HPLC-MS/MS) was proposed. Biological samples were prepared by precipitating proteins using MeOH. The chromatographic separation used a Zorbax Eclipse Plus C18 column with gradient elution. A Shimadzu 8040 triple quadrupole mass spectrometer in multiple-reaction-monitoring mode (+MRM) with chemical ionization at atmospheric pressure (APCI) was used to determine the molecular ion of flupirtine with m/z 305.2. Acalibration curve for flupirtine was linear (R = 0.994) in the concentration range 25 – 2,500 ng/mL with a lower detection limit of 25 ng/mL. Validation of the method indicated that it was highly sensitive, specific, accurate, and precise and that the analyte was stable. The method was successfully applied to comparative pharmacokinetic studies of drugs containing flupirtine.

About the authors

L. M. Krasnykh

Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

Author for correspondence.
Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051

T. A. Rodina

Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051

E. S. Mel’nikov

I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)

Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Trubetskaya St., Moscow, 119991

G. F. Vasilenko

Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation

Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051

V. V. Smirnov

Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)

Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991

A. V. Sokolov

Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)

Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991

V. V. Arkhipov

Scientific Center for Expert Evaluation of Medical Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)

Email: lkrasnykhLM59@mail.ru
Russian Federation, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies